Related Experiment Video

Updated: Jul 27, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Alectinib for treating patients with metastatic

Daniel Samacá-Samacá1, Laura Prieto-Pinto2, Andrés Yepes Peréz3

  • 1IQVIA, Real World Insights, Bogotá, Colombia.

Lung Cancer Management
|June 8, 2023
PubMed
Abstract

Insights

Alectinib demonstrates superior efficacy and a favorable safety profile compared to crizotinib for ALK-positive non-small cell lung cancer (NSCLC). This analysis confirms alectinib

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer (NSCLC) is a distinct subtype.
  • Targeted therapies, including ALK inhibitors, have revolutionized treatment paradigms.

Purpose of the Study:

  • To compare the efficacy and safety of alectinib against other ALK inhibitors.
  • Evaluate treatment outcomes in patients with metastatic or locally advanced ALK-positive NSCLC.

Main Methods:

  • Systematic literature review up to November 2021.
  • Frequentist network meta-analyses (random effects model).
  • GRADE evidence profile assessment.

Main Results:

  • Alectinib improved overall survival versus crizotinib.
  • Alectinib demonstrated superior progression-free survival versus crizotinib and ceritinib.
  • Alectinib showed comparable efficacy to second- and third-generation inhibitors, with a favorable safety profile.

Conclusions:

  • Alectinib is an effective and safe treatment option for ALK-positive NSCLC.
  • Alectinib offers significant survival benefits over older ALK inhibitors.
  • Further research may explore long-term outcomes and comparative effectiveness.
Keywords:
anaplastic lymphoma kinasecarcinomaneoplasm metastasisnetwork meta-analysisnon-small-cell lung

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
213
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K